Právní předpis byl sestaven k datu 19.12.2013.
Zobrazené znění právního předpisu je účinné od 25.12.2012 do 19.12.2013.
97
SDĚLENÍ
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,
xxxxxx se xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx zahraničních věcí x. 58/2007 Xx. x. x., x. 46/2008 Xx. x. x. x x. 47/2012 Xx. x. x. o Mezinárodní xxxxxx proti xxxxxxx xx xxxxxx
Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, xx dne 16. xxxxxxxxx 2011 xxxx generální ředitelkou XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Seznamu xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx.1)
X novým xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Parlament Xxxxx republiky.
Xxxx xxxxx Xxxxxxx X xxxxxxxxx x xxxxxxxx x xxxxxxx x xxxxxxx 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2012 x xxxxx dnem xxxxxxxxx x platnost x xxx Xxxxxx xxxxxxxxx. Xxxx xxxxxx xxxxxx znění Xxxxxxx X v xxxxxxxx xxxxxxxx platit xxxxx Xxxxxxx X Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx platné xx 1. xxxxx 2011 a vyhlášené xxx č. 47/2012 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx X x xxxx xxxxxxx xx českého jazyka xx xxxxxxxxx xxxxxxxx.
1) Mezinárodní xxxxxx proti xxxxxxx xx xxxxxx xxxxxxx xxx 19. října 2005 x Xxxxxx xxxx xxxxxxxxx xxx č. 58/2007 Sb. m. s.
XXXXXXXXXXX XXXXXX XXXXX DOPINGU XX XXXXXX
Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx
Xxxxx, 1. xxxxx 2012
XXXXXX XXXXXXXXXX XXXXX X XXXXX XXXXXXX XXX XXX 2012
SVĚTOVÝ XXXXXXXXXXXXX XXXXX
Platný xx 1. xxxxx 2012
Xxxxx xxxxxx 4.2.2 Xxxxxxxxx antidopingového xxxxxx xxxxxxx Xxxxxxxx xxxxx budou považovány xx "Specifické xxxxx" xxxxx xxxxx xx xxxxxx S1, S2, X4.4, X4.5 x X6(x) x Xxxxxxxxxx xxxxx M1, X2 x M3.
LÁTKY X XXXXXX XXXXXXXX XXXXX (PŘI SOUTĚŽI X XXXX XXXXXX) |
XXXXXXXX LÁTKY
X0. XXXXXXXXXXX XXXXX
Jakákoliv xxxxxxxxxxxxx xxxxx, která xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx aktuálně xxxxxxxxx xxx humánní xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx zdravotnickým regulačním xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx nebo xxxxxxxxx xxxxxx xxxxxxx xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxxxxxx léky), xx xxxxxxxx xxxxx.
X1. XXXXXXXXXX XXXXX
Xxxxxxxxxx xxxxx jsou xxxxxxxx.
1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):
(a) Xxxxxxxx* XXX, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazol); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); desoxymethyltestosteron (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); fluoxymesteron; xxxxxxxxxx; xxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; mestanolon; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); metenolon; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); methylnortestosteron (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); methyltestosteron; metribolon (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); miboleron; xxxxxxxxx; 19-norandrostendion (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; norethandrolon; xxxxxxxxxxxx; xxxxxxxx; oxandrolon; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxxxxx [3,2-x]xxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); xxxxxxxxx x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** XXX, pokud xxxx podány xxxxxxxx:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), dihydrotestosteron, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA), xxxxxxxxxxx x xxxxxx xxxxxxxxxx x isomery, xxx xx x omezením xxxxx na xx:
5α-xxxxxxxxx-3α,17α-xxxx | 5-xxxxxxxxxxxxx (androst-5-en-3,17-dion) |
5α-xxxxxxxxx-3α,17β-xxxx | |
5α-androstan-3β,17α-diol | xxx-xxxxxxxxxxxxxxxxxx |
5α-xxxxxxxxx-3β,17β-xxxx | epitestosteron |
xxxxxxx-4-xx-3α,17α-xxxx | 3α-hydroxy-5αandrostan-17-on |
xxxxxxx-4-xx-3α,17β-xxxx | 3β-xxxxxxx-5αxxxxxxxxx-17-xx |
xxxxxxx-5-xx-3β,17α-xxxx | 7α-hydroxy-DHEA |
xxxxxxx-5-xx-3α,17α-xxxx | 7β-xxxxxxx-XXXX |
xxxxxxx-5-xx-3α,17β-xxxX | 7-xxxx-XXXX |
xxxxxxx-5-xx-3β,17α-xxxx | 19-norandrosteron |
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx) | 19-xxxxxxxxxxxxxxxxx |
2. Xxxxxxx xxxxxxxxxx xxxxx, zahrnující:
Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (SARM), xxxxxxx, xxxxxxx, zilpaterol, ale xx x xxxxxxxx xxxxx xx xx.
Xxx xxxxx skupiny xxxx xxxxx: * "xxxxxxxx" xx xxxxxxxx x xxxxx, kterou xxxx není xxxxxxxx xxxxxxx xxxxxxxxxx přirozeně. ** "xxxxxxxxx " xx xxxxxxxx x xxxxx, xxxxxx xxxx xxxx produkovat xxxxxxxxx. |
S2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX X XXXXXXXX XXXXX
Xxxxxxxxxxx látky a xxxxxx uvolňující xxxxxxx xxxx xxxxxxxx:
1. Xxxxx xxxxxxxxxxx erytropoesu (xxxx. xxxxxxxxxxxx (XXX), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx xxxxxxx vyvolávajícího xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx beta (XXXX), xxxxxxxxxxx /Xxxxxxxx/);
2. Xxxxxxxxxxxxxxxxxx (XX) x Xxxxxxxxxxxx xxxxxx (XX) x xxxx;
3. Insuliny;
4. Xxxxxxxxxxxxxx;
5. Růstový xxxxxx (XX), xxxxxxxxxxxxx xxxxxxx faktory (XXXx), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), xxxxxxxx xxxxxxx xxxxxxx xxxxxx-1 (IGF-1), xxxxxxxxxx xxxxxxx xxxxxxx (XXX), xxxxxxx xxxxxx xxxxxxxx z krevních xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX), xxxxxx jako xxxxxxxxx xxxx xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx xxxx degradaci xxxxxxxx xxxxx, xxxxx x xxxxxx, krevní zásobení, xxxxxxx energie, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx;
x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.
S3. XXXX2- XXXXXXXX
Všichni xxxx-2 agonisté (xxxxxx xxxx případných xxxxxxxxx xxxxxxx) jsou zakázáni xxxxx xxxxxxxxxxx (xxxxxxxxx 1600 xxxxxxxxxx za 24 xxxxx), xxxxxxxxxxx (xxxxxxxxx 36 mikrogramů xx 24 xxxxx) x xxxxxxxxxxx xxxxx xxxx xxxxxx v xxxxxxxx x xxxxxxx x doporučeným xxxxxxxx xxxxxxx xxxxxxx.
Xxxxxxxxxx xxxxxxxxxxx x xxxx x koncentraci xxxxx xxx 1000 xx/xx x přítomnost xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx než 30 ng/ml nebude xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, ale xxxx považována xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx sportovec xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou xxxxxx, xx xxxxxxxxxx výsledek xxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx xxxxx než xxxx xxxxxxx xxxxxxx.
X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX
Zakázané xx xxxxxxxxxxx:
1. Xxxxxxxxxx xxxxxxxx, zahrnující:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-oxo),exemestan, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx xx s xxxxxxxx xxxxx na xx.
2. Xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně.
3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:
Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, ale xx x omezením xxxxx xx ně.
4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, xxx xx x xxxxxxxx pouze xx xx.
5. Xxxxxxxxxxx modulátory: Receptor xxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxxx δ (XXXXδ) agonists/ (xxxx. XX 1516) x Xxxxxxxx xxxxxxxxxxxxxxx xxx aktivované XXX x součinnosti x XXXX xxxxx /XXXXδ-XXX-xxxxxxxxx xxxxxxx xxxxxx (XXXX) xxxx xxxxxxxx/ (xxxx. XXXXX)
X5. DIURETIKA X XXXXXXX MASKOVACÍ XXXXX
Maskovací xxxxx xxxx xxxxxxxx. Xxxxxxxx:
Xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxx. glycerol, xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx x další xxxxx s podobnými xxxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxxxx xxxxxxxxxxxx xxx xxxxx anestézi xxxx xxxxxxxx.
Xxxxxxxxx zahrnují:
Xxxxxxxxxxxx, amilorid, xxxxxxxxx, xxxxxxxxx, chlortalidon, indapamid, xxxxxxxx, xxxxxxxx etakrynová, xxxxxxxxx, spironolakton, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, hydrochlorothiazid, xxxxxxxxxxxxx), triamteren x xxxxx xxxxx s xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx drospirenonu, xxxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx).
Pro xxxxxxx (Xxx Soutěži, xxxxxxxx Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx limitem (xx. formoterol, xxxxxxxxxx, xxxxxx, xxxxx, efedrin, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx xxxxxxx s xxxxxxxxxx xxxx jinou xxxxxxxxx xxxxxx je xxxxxxxxxx xxxxxxx xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx na xxxx xxxxx xxxxx x xx, xxxxx xxx xxxx xxxxxxx xx diuretikum xxxx xxxxx maskovací látku.
XXXXXXXX XXXXXX
X1. XXXXXXXXX XXXXXXX XXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxx doping, xxxxxx xxxxxxx autologní, xxxxxxxxx xxxx xxxxxxxxxxx xxxx nebo červených xxxxxxx x xxx xxxxxxxxx xxxxxxxx jakéhokoliv xxxxxx.
2. Xxxxx xxxxxxxxx xxxxxxxx, přenosu xxxx xxxxxxx xxxxxxx, xxxxxxxxxx modifikované xxxxxxxxxxxxx xxxxxxxx (xxxx.xxxxxx xxxxxxxx xxxxxxxx na xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (RSR13), xxx xx x xxxxxxxx pouze na xx. Xxxxxxxx xxxxxxx xxxxxxxx xxxx.
X2. XXXXXXXX A XXXXXXXXX XXXXXXXXXX
Zakázané xx xxxxxxxxxxx:
1. Podvádění, xxxx xxxxx x xxxxxx, za účelem xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx xx xxxxxxxx. Xx xxxxxxxx záměnu x/xxxx xxxxxx (xxxx. proteázami) xxxx, xxx ne x xxxxxxxx xxxxx xx xx.
2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx než 50 xx xx 6 xxxxx xxxx xxxxxxxx xxxxx infuzí xxxxxxxxx přijatých x xxxxxxx nemocničních xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxx.
3. Xxxxxxxx xxxxx, manipulace x xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxx xxxx do xxxxxxxxx systému xx xxxxxxxx.
X3. XXXXXX XXXXXX
X xxxxxx xxxxxxxxxx ke xxxxxxx xxxxxxxxxxx xxxxxx je xxxxxxxx xxxxxxxxxxx:
1. Xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxxx;
2. Použití normálních xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx;
XXXXX X XXXXXX XXXXXXXX XXX XXXXXXX |
Xxxxx xxxxxxxxx XX xx X5 a X1 xx X3 xxxxxxxxx xxxx jsou Xxx Soutěži xxxxxxxx x xxxxxxxxxxx skupiny:
XXXXXXXX XXXXX
X6. XXXXXXXXXXX
Xxxxxxx stimulancia (xxxxxx obou jejich xxxxxxxxxx optických xxxxxxx) xxxx xxxxxxxx, x xxxxxxxx xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxxxx zahrnutých do Xxxxxxxxxxxxxx xxxxxxxx pro xxx 2012*.
Xxxxxxxxxxx xxxxxxxx:
(x) Xxxxxxxxxxxx xxxxxxxxxxx:
Adrafinil, xxxxxxxxxx, xxxxxxxxxxx, amfetamin, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, dimethylamfetamin, xxxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, fenetylin, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, krotetamid, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx (x-), xxxxxxxxxxxxxxxxxxxxxx, methylendioxymetamfetamin, xxxxxxxx, modafinil, norfenfluramin, x-xxxxxxxxxxxxxxx, prenylamin, xxxxxxxxx.
Xxxxxxxxxxxx, které xxxx xxxxxxxx xxxxxxx v xxxxx xxxxxxxx, je Xxxxxxxxxxx xxxxxx.
(b) Xxxxxxxxxx stimulancia (xxxxxxxx):
Xxxxxxxxx**, katin***, efedrin****, xxxxxxxx, etilefrin, fenbutrazát, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx****, xxxxxxxxxxxxx, methylhexanamin (xxxxxxxxxxxxxxxxx), xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, parahydroxyamfetamin, xxxxxxx, pentetrazol, propylhexedrin, xxxxxxxxxxxxx*****xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx biologickými xxxxxx.
* Xxxxxxxxxxx xxxxx xxxxxxxx do Monitorovacího xxxxxxxx 2012 (bupropion, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, pipradrol, xxxxxxxx) xxxxxx považovány xx Xxxxxxxx xxxxx.
** Xxxxxxx xxxxxx xxxxxxxxxx (xxxx. nosní, xxxx xxxxxxxx) nebo jeho xxxxxx xxxxxxxx x xxxxxxxxx anestetiky xxxx xxxxxxxx.
*** Katin xx xxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 mikrogramů x 1 ml xxxx.
**** Xxxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxx při xxxxxxxxxxx xxxxx než 10 xxxxxxxxxx x 1 xx xxxx.
***** Xxxxxxxxxxxxx xx xxxxxxx, xxxxx xxxx koncentrace x xxxx xx xxxxx xxx 150 xxxxxxxxxx xx mililitr
X7. XXXXXXXXX
Zakázané xx následujíci:
Buprenorfin, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx x jeho xxxxxxxx, xxxxxxxxxxx, metadon, morfin, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx.
S8. KANABINOIDY
Xxxxxxxx (např. xxxxx, xxxxxx x xxxxxxxxx) xxxx xxxxxxxxxx delta9tetrahydrokanabinol (XXX) a xxxxxxxxxxxxxx (xxxx. "Xxxxx" /xxxxxxxxxx XXX018, XXX073/ x XX-210) jsou xxxxxxxx.
X9. XXXXXXXXXXXXXXXXXXXX
Všechny xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, nitrožilní xxxx xxxxxxxxxxxxx aplikací xxxx xxxxxxxx.
XXXXX XXXXXXXX X XXXXXXXX XXXXXXXX |
X1. XXXXXXX
Xxxxxxx (xxxxxx) xx zakázaný xxxxx Xxx Soutěži x xxxxxxxxxxxxx xxxxxxxx. Detekce xx xxxx xxxxxxxx xxxxxxxx xxxxxxxx a/nebo xxxxxxxx xxxx. Prahová xxxxxxx pro xxxxxxxx xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) xx 0.10 x/x.
∙ Automobilový xxxxx (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx a xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (XXXX)
∙ Xxxxxxxxxxx xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (XXX)
X2. BETA-BLOKÁTORY
Pokud xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Xxx Soutěži x následujících xxxxxxxx.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Billiard (xxxxxxx xxxxxxxxxx) (WCBS)
∙ Xxxxx (FMB)
∙ Xxxx (XXX)
∙ Xxxxxxx x xxxxxxx (XXX)
∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx (XXX)
∙ Xxxxxxxxxxx (FITA, IPC) (xxxxxxxx také Xxxx xxxxxx)
∙ Lyžování (XXX) - xxxxx xx lyžích x xxxxxxxxxxx lyžování-skoky x X-xxxxx,x xxxxxxxxx X-xxxxx x "big air"
∙ Xxxxxxxx x xxxxxxx sporty (CMSB)
∙ Xxxxxxx (ISSF, XXX) (zakázané xxxx Xxxx xxxxxx)
∙ Xxxxx (XXX)
∙ Xxxxx motorismus (XxX)
Xxxx-xxxxxxxxx zahrnují xxxxxxxxxxx xxxxx:
Xxxxxxxxxx, alprenolol, xxxxxxxx, xxxxxxxxx, bisoprolol, xxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, labetalol, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, oxprenolol, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, timolol, xxx ne x xxxxxxxx xxxxx xx xx.
Informace
Xxxxxx xxxxxxx č. 97/2012 Xx. x. x. xxxxx xxxxxxxxx xxxx 25.12.2012.
Xxxxxx xxxxxxx x. 97/2012 Xx. x. x. xxx xxxxxx xxxxxxx xxxxxxxxx č. 98/2013 Sb. m. s. x účinností od 20.12.2013.
Znění xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx není xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx.